Home › Neurofibrosarcoma › NCT07298083
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
RecruitingObservational study
Who can join
Ages 1 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care. 2. Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age \< 18 years, both parents' signatures will be requested. 3. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. 4. Recurrent or primary disease. 5. Patients who are \> 18 years should have the ability to understand and the willingness to sign a written informed consent document. 6. English and non-English speaking patients. Exclusion Criteria: 1. Adult patients with cognitive impairment requiring a legally authorized representative for consent. 2. Patients under age 1 and neonates. 3. Patients who are pregnant and undergoing surgery for MPNST are not eligible.
About the study
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
Sponsor: M.D. Anderson Cancer Center · Participants: 60 · Started: Apr 2, 2026
Contact the study team
- Keila Torres, MD,PHD · Phone: (713) 792-4242
Official record on ClinicalTrials.gov — NCT07298083
Locations in the U.S.
| Texas | The University of Texas M. D. Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.